Biotech and Pharmaceuticals
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! A highly popular group of weight loss and diabetes drugs is still hard […]
Read More
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly’s weight loss drug dominance
The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival. Amgen […]
Read More
Generative AI will be coming up with new prescription drugs all on its own in the around long run
Eli Lilly chief information and facts and digital officer Diogo Rau was recently concerned in some experiments in the business office, but not the common drug study work that you could assume to be amid the lab tinkering inside a main pharmaceutical business. Lilly has been utilizing generative AI to lookup as a result of […]
Read More
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Pavlo Gonchar | Lightrocket | Getty Images Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, […]
Read More
Wegovy maker Novo Nordisk down 4%, heads for worst day considering the fact that Oct
Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% decline on Thursday as analysts pored about the facts of the firm’s first-quarter final results and monitored a opportunity rival body weight reduction procedure. It puts the stock on observe for its sharpest everyday drop considering the fact that Oct 2023, in accordance to […]
Read More
Amgen scraps experimental weight loss pill, moves forward with injection
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. The announcement is a setback for […]
Read More
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company’s cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The results come as Moderna inches closer to putting another product on the market, which it badly […]
Read More
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts. JB Reed | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie‘s Humira are plummeting as the once-top-selling drug fights competition from cheaper […]
Read More
Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.
Johnson & Johnson on Wednesday said it will pay $6.5 billion to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer. The deal would allow J&J to resolve the lawsuits through a third bankruptcy filing of a subsidiary company, LTL Management. More CNBC health coverage It […]
Read More
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
Jakub Porzycki | Nurphoto | Getty Images Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products. The company now expects to book adjusted earnings of $2.15 to $2.35 per share for the fiscal year, up from […]
Read More